Vytorin researchers call for new data-release rules

Prompted by Merck and Schering-Plough's early release of the SEAS study data on Vytorin, Duke University researchers are calling for new rules governing the release of trial data; they'd invest third parties with more power to monitor research as it's going on and guard data once it's generated. Report

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Intent-driven audiences are inspired to make health-improving changes after a positive online experience. Find out what they’re driven to do.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.